Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Keynote speech: progress with a purpose

Andrew C von Eschenbach1

  • 1National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-2590, USA. ncipressofficers@mail.nih.gov

Cancer
|October 26, 2005
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA.

The New England journal of medicine·2025
Same author

Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.

Drugs·2021
Same author

Seven Former FDA Commissioners: The FDA Should Be An Independent Federal Agency.

Health affairs (Project Hope)·2019
Same author

Health, Wealth, and the 21st Century Cures Act.

JAMA oncology·2015
Same author

Cancer informatics vision: caBIG.

Cancer informatics·2009
Same author

Expediting the availability of drugs for US patients with cancer.

Nature clinical practice. Urology·2008
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles